Article Correctness Is Author's Responsibility: Seurat therapeutics announces novel mechanisms from rat migraine model of intranasal IGF-1

(Polsky Center for Entrepreneurship and Innovation) Studies demonstrated intranasal Insulin-like Growth Factor-1 (IGF-1) safely and effectively dampens activation of the trigeminal system pain pathway in rats, a known site of pain origin in migraine headachesThe results support further development of nasal IGF-1 as a novel treatment for migraines, which afflict 39 million people in the USA.